


2016-2020 Strategy: Progress, Challenges and Risks

BOARD MEETING: Anuradha Gupta, 4-5 December 2019, Delhi




Alliance on track to achieve its 2020 mission indicators




Dramatic decline in child deaths

Decline in under-5 mortality
in Gavi supported countries




Much steeper decline in deaths
from vaccine-preventable diseases



Dramatic decline in child deaths



Steep decline in four diseases targeted by Gavi



Immunisation is succeeding in reaching more households, including the poorest

Highest coverage

and most equitable




Note: based on Gavi68 with a Demographic and Health Survey or Multiple Indicator Cluster Survey, latest survey for each country, 2010-2017. Estimates are averages of country values weighted by appropriate population groups to compute weighted average coverage of a given intervention

Zero dose child is a marker of acute inequity

2 out of 3 zero dose children
live in households surviving on
less than US\$ 1.90 a day



—— US\$ 1.90 —— ◀ poverty line



Opportunity for **multi-agency,**
multi-sectoral action










SG1: Accelerate vaccines

SG2: Strengthen systems


Mixed performance: challenges and risks remain



Significant progress in expanding breadth of protection



Differentiation showing encouraging trends (2015-2018)




PEF Tier 1: Nigeria, India, Pakistan, Indonesia, Ethiopia, DRC, Afghanistan, Chad, Kenya and Uganda

PEF Tier 2 (plus fragile): Somalia, Yemen, Mali, Mozambique, Madagascar, Niger, South Sudan, Haiti, Sudan, PNG, Myanmar, CAR, Burundi, Eritrea and Solomon Island

Progress on equity in countries where Alliance has amplified its focus



PEF Tier 1: Pakistan



Under-immunised **decreased by 8%**



Zero dose* **decreased by 2%**



Wealth equity **improved by 16pp**



Maternal education equity **improved by 7pp**



Fragile: Mali



Under-immunised **decreased by 7%**



Zero dose* **decreased by 24%**




Wealth equity **improved by 16pp**



Maternal education equity **improved by 13pp**

Forging new partnerships in fragile countries




SG3: Improve sustainability




Gavi continues to lead the way on sustainability


CO-FINANCING & SELF-FINANCING




COUNTRIES INVESTMENT IN IMMUNISATION



CO-FINANCING COMMITMENTS




TRANSITION STATUS



Focused engagement in transitioning and transitioned countries

Transitioning countries: 5 on track, 3 not yet there



Transitioned countries showing strong performance



15 countries have transitioned out of Gavi support



14 of 15 countries have **sustained above 90% or improved coverage**



All 15 countries have **continued to procure vaccines introduced** with Gavi support


SG4: Market shaping



Progress on price reduction and innovation; continued challenges on supply and healthy markets

Improving

VACCINE PRICE REDUCTION




Challenges

SUPPLY SECURITY




Stable

HEALTHY MARKET DYNAMICS



Increasing

VACCINE INNOVATION




Most cervical cancer deaths are in poor countries

Supply of ~35m doses versus country demand of ~80m*

13m girls reached versus 40m^ target

300k future deaths averted versus 900k target

Cervical cancer deaths,
cervix uteri (per 100,000)



'It always seems
impossible until it is done'

Nelson Mandela

THANK YOU

